InnoCare's Mesutoclax Receives Breakthrough Therapy Designation from China's NMPA
BEIJING--(BUSINESS WIRE)--May 11, 2025--
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China!
Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor, developed as monotherapy or in combination with orelabrutinib for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other non-Hodgkin's lymphomas (NHLs), and as well as acute myeloid leukemia (AML). BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'We are delighted that mesutoclax has been granted Breakthrough Therapy Designation, which will help expedite multi-center, multi-indication clinical trials for mesutoclax in China and globally to benefit patients as early as possible.'
Clinical trials of mesutoclax are ongoing both in China and globally, including a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of CLL/SLL patients, as well as a clinical trial of mesutoclax for the treatment of AML.
The Breakthrough Therapy Designation (BTD) by the CDE aims to accelerate the clinical development of new drugs that demonstrate significant clinical advantages. New drugs granted BTD are typically intended for diseases that are life-threatening or severely impair quality of life, and have demonstrated clear advantages in efficacy or safety during clinical trials.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250511947346/en/
CONTACT: Media
Chunhua Lu
86-10-66609879
[email protected]
86-10-66609999
[email protected]
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: InnoCare Pharma
Copyright Business Wire 2025.
PUB: 05/11/2025 08:39 PM/DISC: 05/11/2025 08:39 PM
http://www.businesswire.com/news/home/20250511947346/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
29 minutes ago
- Forbes
China Accuses US Of Violating Trade Pact—Rejects Trump's Allegation
Chinese authorities on Monday accused the U.S. of violating a recent trade pact that both agreed to in Geneva last month, as they dismissed President Donald Trump's allegation about Beijing breaching the agreement, a move that could signal a further escalation in trade tensions between the two countries, which could potentially jeopardize last month's tariff truce. China's Commerce Ministry accused the U.S. of violating a trade deal agreed in Geneva by imposing ... More additional chip restrictions and canceling Chinese student visas. In a press briefing, a Chinese Commerce Ministry spokesperson dismissed Trump's comments accusing China of violating the agreement, saying Beijing has worked 'to strictly implement and actively safeguard the Geneva deal.' The spokesperson noted that China had acted in accordance with the deal to cancel or suspend 'relevant tariffs and non-tariff measures' it had taken as retaliation against the U.S. government's reciprocal tariffs. The spokesperson then accused the U.S. of introducing ' a number of discriminatory restrictive measures against China' after the talks, citing expanded export controls on AI chips and other chip-building technology. The official also criticized the U.S. government's crackdown on Chinese student visas, saying these actions violated the consensus reached between Trump and Chinese President Xi Jinping in a phone call on January 17. The spokesperson then warned that if the U.S. continues to take actions that damage China, Beijing will 'take resolute and forceful measures to safeguard its legitimate rights and interests.' In a post on his Truth Social platform on Friday, Trump said: 'China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US,' without specifying how it had done so. The president then signalled that the U.S. may retaliate against this alleged non-compliance, saying: 'So much for being Mr. NICE GUY!' In his post, the president claimed his tariffs had put China in 'grave economic danger' and he made a 'FAST DEAL' in Geneva, 'in order to save them from what I thought was going to be a very bad situation.'
Yahoo
34 minutes ago
- Yahoo
India finalises new EV scheme, offers import tax cuts for local production
(Reuters) -India on Monday announced a scheme that includes significant import tax cuts for foreign automakers that commit to investing in manufacturing electric cars in the country. Under a rewamped scheme, companies will be allowed to import a limited number of electric cars at a lower import duty of 15% versus the current 70% duty if they commit to investing $486 million to build EVs in the country, the ministry of heavy industries said in a statement. Carmakers including Mercedes Benz, Volkswagen, Skoda, Hyundai and Kia have already shown interest in the new policy, a federal minister told reporters in a media briefing on Monday. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
36 minutes ago
- Bloomberg
India to Open Flagship EV Making Policy to Lure Global Giants
India is set to open applications for its flagship policy offering lower import duties to global electric vehicle makers in exchange for manufacturing in India, people familiar with the matter said. The policy, that was announced in March 2024, offers to slash duty to 15% on any imported electric car priced from $35,000 if they invest at least 41.5 billion rupees, or about $500 million, to set up a local plant within three years. Up to 8,000 cars yearly can be imported at this reduced rate.
